GPR35 Modulators for Inflammatory Bowel Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatment options for inflammatory bowel diseases like Crohn's disease and ulcerative colitis are limited, with many patients not responding to anti-TNF therapy, necessitating the development of targeted treatments that address the underlying immunopathogenesis.
Innovation Solution
Development of compounds of Formula (I) and their pharmaceutically acceptable salts or solvates, which modulate GPR35 activity, are administered to patients with inflammatory bowel diseases to provide a therapeutically effective treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-TNF therapy is administered to treat inflammatory bowel disease, then some patients experience disease remission, but nearly half of all patients do not respond to the therapy or experience loss of response over time
Solution Approach 1:
The patent changes the therapeutic parameter from anti-TNF mechanism to GPR35 receptor modulation. By identifying and targeting a different receptor pathway (GPR35) that is involved in inflammatory bowel disease pathogenesis, the invention provides an alternative mechanism of action that can be effective in patients who do not respond to anti-TNF therapy, thereby improving overall treatment response rates and adaptability across different patient populations
Solution Approach 2:
The patent introduces a new therapeutic intermediary (GPR35 modulator compound) that acts as a mediator between the treatment and the disease pathology. This intermediary targets a different receptor system (GPR35) compared to existing anti-TNF therapies, providing a novel pathway for modulating immune response and inflammation in IBD patients who have failed or do not respond to conventional treatments
2Object-affected harmful factors
If current therapeutic regimens are used for inflammatory bowel disease, then some symptoms are managed, but the underlying immunopathogenesis is not adequately addressed and disease severity progresses in non-responders
Solution Approach 1:
The patent extracts and targets a specific receptor component (GPR35) that plays a key role in the immunopathogenesis of inflammatory bowel disease. By focusing on this specific receptor rather than using broad-spectrum immunosuppression, the invention aims to address the underlying disease mechanism more precisely, potentially preventing disease progression in patients who do not respond to conventional symptom-management approaches
Solution Approach 2:
The patent changes the therapeutic target parameter from TNF-alpha pathway to GPR35 receptor pathway. This parameter change represents a shift from targeting a cytokine to targeting a G-protein coupled receptor, providing a novel mechanism for addressing the underlying immunopathogenesis of IBD and potentially controlling disease progression in a different subset of patients
Data Source
AI summary
Described herein are GPR35 modulators and methods of using these compounds in the treatment of diseases, disorders or conditions. Also described herein are pharmaceutical compositions containing such compounds.